share_log

Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned

Benzinga ·  Dec 24 20:04

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets).

The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment